Sugi Predict

Sugi Predict / Compounds / SCHEMBL4988995

SCHEMBL4988995

SCHEMBL4988995

CCN(CC)c1ccc(N/C=C2/C(=O)Nc3ccccc32)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ TDP1 Q9NUW8 3/20 0.42
▸ RET P07949 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ MAPT P10636 5/20 0.41
▸ NPSR1 Q6W5P4 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ TGM2 P21980 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ ALK Q9UM73 3/20 0.41
▸ MAPK1 P28482 3/20 0.40
▸ PKM P14618 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ MDM2 Q00987 1/20 0.39
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4989000 1.00 NPC1 (0.45) NPC1SMN1; SMN2TDP1RETALDH1A1
SCHEMBL4984951 0.92 SMN1; SMN2 (0.39) NPC1SMN1; SMN2TDP1RETALDH1A1
SCHEMBL4984953 0.92 SMN1; SMN2 (0.39) NPC1SMN1; SMN2TDP1RETALDH1A1
SCHEMBL4992680 0.92 SMN1; SMN2 (0.41) NPC1SMN1; SMN2TDP1RETALDH1A1
SCHEMBL4992675 0.92 SMN1; SMN2 (0.41) NPC1SMN1; SMN2TDP1RETALDH1A1
SCHEMBL4987002 0.90 SMN1; SMN2 (0.37) NPC1SMN1; SMN2TDP1RETALDH1A1
SCHEMBL4987000 0.90 SMN1; SMN2 (0.37) NPC1SMN1; SMN2TDP1RETALDH1A1
SCHEMBL4994900 0.88 TGM2 (0.48) ALDH1A1TGM2KDRMDM2MEN1
SCHEMBL4994905 0.88 TGM2 (0.48) ALDH1A1TGM2KDRMDM2MEN1
SCHEMBL4994834 0.88 FLT3 (0.45) RETLMNAHTTALKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 — — US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 — — US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 — — US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 — — US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 — — US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 — — US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 — — US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 — — US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 — — US disclosed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 — — EP disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 — — US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 — — US disclosed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NPC1 4010/4885SMN1; SMN2 4396/4885TDP1 1661/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NPC1 4010/4885SMN1; SMN2 4396/4885TDP1 1661/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NPC1 4010/4885SMN1; SMN2 4396/4885TDP1 1661/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NPC1 4010/4885SMN1; SMN2 4396/4885TDP1 1661/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NPC1 4010/4885SMN1; SMN2 4396/4885TDP1 1661/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NPC1 4010/4885SMN1; SMN2 4396/4885TDP1 1661/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 NPC1 4010/4885SMN1; SMN2 4396/4885TDP1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.